Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72238
Title: | 台灣紫芝多醣體調節小鼠過敏型氣喘與腸道菌相之研究 Regulation of mouse allergic asthma and gut microbiota by Ganoderma formosanum polysaccharides |
Authors: | Ching-Han Lin 林敬涵 |
Advisor: | 陳俊任(Chun-Jen Chen) |
Keyword: | 台灣紫芝,多醣體,過敏型氣喘,嗜酸性球,腸道菌相, Ganoderma formosanum,polysaccharide,allergic asthma,eosinophil,gut microbiota, |
Publication Year : | 2020 |
Degree: | 碩士 |
Abstract: | 台灣紫芝 (Ganoderma formosanum) 為台灣靈芝屬之特有品種,本實驗室透過液態深層發酵培養法生產靈芝胞外多醣體,並經膠體過濾法純化出PS-F2。在先前研究中發現,利用腹腔注射的方式給予PS-F2能夠減少過敏型氣喘所造成之呼吸道阻力並降低肺部發炎反應;本研究主要探討,連續口服PS-F2是否也能夠降低過敏型氣喘的症狀並減少肺部發炎反應。在本動物模型中重複以OVA和鋁鹽誘導免疫作用並以OVA自鼻腔刺激誘導過敏型氣喘。研究結果顯示,口服低劑量 (125 mg/kg) PS-F2能夠減輕小鼠過敏型氣喘所造成之呼吸道阻力並且有效降低具OVA抗原專一性抗體IgG1以及IgG2a在血清中之含量,但無法降低肺部發炎反應。口服高劑量 (250 mg/kg) PS-F2未能減輕小鼠過敏型氣喘所造成之呼吸道阻力,亦無法下調具有OVA專一性抗體IgE、IgG1以及IgG2a的產生;然而,浸潤至肺部當中的嗜酸性球與第二型免疫反應相關細胞激素的產生有下調的情形。本研究另一部分探討,腸道微生物是否利用PS-F2改變腸道中菌相之組成,以及腸道菌相是否在過敏型氣喘小鼠中與PS-F2之免疫調節作用有關。分析小鼠糞便中所抽取之16S rDNA發現,誘導過敏型氣喘發生後,降低小鼠腸道菌相之α多樣性,但攝取PS-F2並無法改變α多樣性;過敏型氣喘明顯改變小鼠腸道菌相之β多樣性,而攝取PS-F2無法進一步改變β多樣性。綜合來說,攝取PS-F2無法明顯改變過敏型氣喘小鼠之腸道菌相,而攝取PS-F2是否影響過敏型氣喘仍需要進一步驗證。 Ganoderma formosanum is the endemic species of Ganoderma isolated in Taiwan. We produced extracellular polysaccharides of G. formosanum by submerged culture and purified the second fraction of polysaccharides (PS-F2) by gel filtration. In the previous study, we found that PS-F2 treatment by intraperitoneal injection could alleviate the symptom of allergic asthma and downregulate the inflammation in the lung. In this study, we investigated whether continuous PS-F2 treatment by oral gavage could also alleviate chicken ovalbumin (OVA)-induced allergic asthma and downregulate lung inflammation in mice. In this model, mice were sensitized by repeated immunization with OVA and alum, followed by intranasal challenge of OVA to induced acute asthma. The results showed that PS-F2 treatment at a lower dose (125 mg/kg) could alleviate airway hyperresponsiveness (AHR) and decrease serum levels of OVA-specific IgG1 and IgG2a, although pulmonary inflammation was not affected. PS-F2 treatment at a higher dose (250 mg/kg) did not affect AHR and serum levels of OVA-specific IgE, IgG1 and IgG2a; however, eosinophil infiltration in the lung and the production of type 2 immunity-associated cytokine were downregulated. In this study, we also explored whether the composition of gut microbiota was altered by PS-F2 administration, and whether it was associated with the immunomodulatory effect of PS-F2 in mice with allergic asthma. By analyzing fecal 16s rDNA, we found that the α diversity of gut microbiota was reduced in OVA-immunized mice, but PS-F2 treatment did not change the α diversity of gut microbiota. OVA immunization significantly changed the β diversity of gut microbiota, which was not further altered by PS-F2 treatment. Taken together, PS-F2 treatment did not significantly alter the composition of gut microbiota, and whether PS-F2 administration affects allergic asthma will require further validation. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72238 |
DOI: | 10.6342/NTU202004211 |
Fulltext Rights: | 有償授權 |
Appears in Collections: | 生化科技學系 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
U0001-1609202012081000.pdf Restricted Access | 6.18 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.